AUY922
Sponsors
Novartis Pharmaceuticals, Swedish Medical Center, Texas Tech University Health Sciences Center, El Paso, National Health Research Institutes, Taiwan, SCRI Development Innovations, LLC
Conditions
Adenocarcinoma of the ColonAdenocarcinoma of the PancreasAdenocarcinoma of the RectumAdvanced Gastric CancerAdvanced HER2-positive Breast CancerAdvanced Non Small Cell Lung Cancer (NSCLC)Advanced Solid TumorsAnaplastic Lymphoma Kinase (ALK)
Phase 1
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.
CompletedNCT00708292
Start: 2008-07-31End: 2011-01-31Updated: 2020-12-17
Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan
CompletedNCT01132625
Start: 2008-11-30End: 2012-05-31Updated: 2020-12-09
Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab
CompletedNCT01271920
Start: 2010-09-30End: 2013-10-31Updated: 2020-12-08
Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
CompletedNCT01294826
Start: 2011-02-28End: 2015-05-31Updated: 2015-06-08
AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer
WithdrawnNCT01361945
Start: 2011-07-31End: 2012-08-31Updated: 2017-05-09
PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer
CompletedNCT01613950
Start: 2012-12-31End: 2014-03-31Updated: 2020-12-09
Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer
CompletedNCT01772797
Start: 2013-06-30End: 2016-01-31Updated: 2020-12-19
Phase 2
Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer
CompletedNCT01084330
Start: 2010-04-30End: 2012-05-31Updated: 2020-12-10
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
CompletedNCT01124864
Start: 2010-10-31End: 2014-08-31Updated: 2016-03-02
A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients
NCT01389583
Start: 2011-10-31End: 2019-10-31Target: 25Updated: 2015-02-25
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
TerminatedNCT01402401
Start: 2011-11-30End: 2013-06-30Updated: 2020-12-10
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
CompletedNCT01404650
Start: 2011-12-31End: 2015-02-28Updated: 2016-10-04
Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy
TerminatedNCT01484860
Start: 2012-01-31End: 2013-08-31Updated: 2019-02-15
A Study of the HSP90 Inhibitor AUY922
TerminatedNCT01485536
Start: 2012-08-31End: 2015-11-30Updated: 2017-01-23
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
TerminatedNCT01646125
Start: 2012-11-23End: 2015-11-04Updated: 2019-07-24
HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET
TerminatedNCT01668173
Start: 2012-08-31End: 2015-05-31Updated: 2016-05-23
AUY922 for Advanced ALK-positive NSCLC
CompletedNCT01752400
Start: 2013-01-31End: 2017-11-30Updated: 2018-03-29
Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
CompletedNCT01854034
Start: 2013-07-31End: 2017-03-31Updated: 2018-04-10
AUY922 in Patient With Stage IV NSCLC
CompletedNCT01922583
Start: 2014-01-31End: 2017-02-28Updated: 2018-07-18